Femtech x AI Company Flora Raises Funds from Ritsumeikan Social Impact Fund, Nagase & Co., PE&HR, etc. - Total Funding Expands to Approximately 500 Million JPY
Flora Inc., a Femtech x AI company, has raised approximately 230 million JPY from Ritsumeikan Social Impact Fund, Nagase Future Fund, PE&HR, and financial institutions, bringing its total accumulated funding to approximately 500 million JPY. The funds will be used to enhance functions and strengthen sales for its B2B Femtech service "Wellflow," expand its "Expert" business that leverages AI and real data to support service development for women's health issues, accelerate overseas expansion of all services, and strengthen its organizational structure.
📋 Article Processing Timeline
- 📰 Published: April 27, 2026 at 20:00
- 🔍 Collected: April 27, 2026 at 11:31
- 🤖 AI Analyzed: April 28, 2026 at 02:47 (15h 15m after Collected)
Flora Inc. (Headquarters: Kyoto City, Kyoto Prefecture; Representative Director: Anna Kreshenko; hereinafter "Flora") is pleased to announce that it has raised a total of approximately 230 million JPY through investments from Ritsumeikan Social Impact Fund Investment Limited Partnership (hereinafter "Ritsumeikan SIF"), Nagase Future Fund No. 1 Investment Limited Partnership (CVC fund of Nagase & Co., Ltd.; hereinafter "NFF"), Saikyo Innovation Investment Limited Partnership (operated by PE&HR Inc.; hereinafter "PE&HR"), and loans from financial institutions. This brings Flora's total accumulated funding to approximately 500 million JPY.
The raised funds will be allocated to enhancing the functions and strengthening the sales system of "Wellflow," a Femtech service for corporations; expanding the "Expert" business, which utilizes AI and real data to support service development and business creation rooted in women's health issues; accelerating the overseas expansion of all services; and strengthening the organizational structure.
**Background of Fundraising and Use of Funds**
In the medical and healthcare fields, a "gender data gap" where research data and clinical trials have often been designed based on male standards, resulting in a lack of data on women's specific health issues, is globally recognized as a problem. In Japan, while women's social advancement is progressing, the impact of health issues specific to each life stage such as menstruation, fertility treatment, pregnancy, postpartum, and menopause on the working environment and productivity has not been sufficiently visualized. According to estimates by the Ministry of Economy, Trade and Industry, labor losses due to women's specific health issues amount to approximately 3.4 trillion JPY annually.
Flora is a Femtech startup from Kyoto with the mission to bridge this "gender data gap" using the power of AI and data. Based on approximately 200,000 users' data accumulated through its consumer app and its unique AI algorithms, Flora has developed and expanded "Wellflow," a Femtech service for corporations (supporting the well-being of female employees), "Flora Expert," a business development and service development support for corporations, and "Moonly," a healthcare app for individuals.
The funds raised in this round are planned to be primarily utilized in the following areas:
- Strengthening functions and expanding business for "Wellflow," a Femtech service for corporations — Enhancing personalized support functions for employees' health issues utilizing AI, expanding functions that contribute to promoting corporate health management, and strengthening sales and marketing systems for acquiring new customers.
- Expanding "Flora Expert" — Building and advancing a business development platform that integrates accumulated women's health data with AI to rapidly conduct hypothesis testing for each company. This aims to suppress sample bias and interpretation variability often occurring in traditional women-focused surveys and marketing, supporting highly accurate insight extraction and decision-making. It contributes to realizing gender-conscious product and business development (gendered innovation).
- Strengthening development of "Moonly," a personal healthcare app — Expanding AI healthcare functions that cover the entire life stage including menstruation, fertility treatment, pregnancy, postpartum, and menopause, and strengthening the data infrastructure. Accelerating growth in Asian markets, including Korea and Taiwan.
- Strengthening organizational structure — Recruiting engineers, data scientists, and business development personnel.
**About the Underwriters in This Round**
Ritsumeikan Social Impact Fund Investment Limited Partnership (Ritsumeikan SIF)
Ritsumeikan SIF is an impact investment fund wholly owned by Ritsumeikan Trust and operated by Plus Social Investment Inc. It aims to achieve both solutions to social issues and economic returns, conducting investment and hands-on support utilizing the university's knowledge and network.
Masato Noike, Representative Director and President, Plus Social Investment Inc.
Ritsumeikan Social Impact Fund Investment Limited Partnership
General Partner: Plus Social Investment Inc.
This fund was established with the objective of supporting challenges in solving social issues, as one embodiment of the "Ritsumeikan Vision 2030: More Freedom to Challenge." Flora Inc., through "Wellflow" and "Moonly," comprehensively supports women's specific health issues. Furthermore, the Flora Expert business, which leverages accumulated data, is believed to break through the issue of "data and research shortage" in this field, creating a foundation for a society where everyone can live easily.
We are confident that these businesses will support the well-being of all people and contribute to the realization of a society where everyone can continue to challenge freely, and we look forward to walking together with Flora.
Nagase Future Fund Investment Limited Partnership (NFF)
Nagase Future Fund Investment Limited Partnership (NFF) is a CVC fund operated by Nagase & Co., Ltd. (TSE Prime: 8012). Nagase & Co. was founded in 1832 as a chemical trading company, specializing in the healthcare and beauty sector.
The raised funds will be allocated to enhancing the functions and strengthening the sales system of "Wellflow," a Femtech service for corporations; expanding the "Expert" business, which utilizes AI and real data to support service development and business creation rooted in women's health issues; accelerating the overseas expansion of all services; and strengthening the organizational structure.
**Background of Fundraising and Use of Funds**
In the medical and healthcare fields, a "gender data gap" where research data and clinical trials have often been designed based on male standards, resulting in a lack of data on women's specific health issues, is globally recognized as a problem. In Japan, while women's social advancement is progressing, the impact of health issues specific to each life stage such as menstruation, fertility treatment, pregnancy, postpartum, and menopause on the working environment and productivity has not been sufficiently visualized. According to estimates by the Ministry of Economy, Trade and Industry, labor losses due to women's specific health issues amount to approximately 3.4 trillion JPY annually.
Flora is a Femtech startup from Kyoto with the mission to bridge this "gender data gap" using the power of AI and data. Based on approximately 200,000 users' data accumulated through its consumer app and its unique AI algorithms, Flora has developed and expanded "Wellflow," a Femtech service for corporations (supporting the well-being of female employees), "Flora Expert," a business development and service development support for corporations, and "Moonly," a healthcare app for individuals.
The funds raised in this round are planned to be primarily utilized in the following areas:
- Strengthening functions and expanding business for "Wellflow," a Femtech service for corporations — Enhancing personalized support functions for employees' health issues utilizing AI, expanding functions that contribute to promoting corporate health management, and strengthening sales and marketing systems for acquiring new customers.
- Expanding "Flora Expert" — Building and advancing a business development platform that integrates accumulated women's health data with AI to rapidly conduct hypothesis testing for each company. This aims to suppress sample bias and interpretation variability often occurring in traditional women-focused surveys and marketing, supporting highly accurate insight extraction and decision-making. It contributes to realizing gender-conscious product and business development (gendered innovation).
- Strengthening development of "Moonly," a personal healthcare app — Expanding AI healthcare functions that cover the entire life stage including menstruation, fertility treatment, pregnancy, postpartum, and menopause, and strengthening the data infrastructure. Accelerating growth in Asian markets, including Korea and Taiwan.
- Strengthening organizational structure — Recruiting engineers, data scientists, and business development personnel.
**About the Underwriters in This Round**
Ritsumeikan Social Impact Fund Investment Limited Partnership (Ritsumeikan SIF)
Ritsumeikan SIF is an impact investment fund wholly owned by Ritsumeikan Trust and operated by Plus Social Investment Inc. It aims to achieve both solutions to social issues and economic returns, conducting investment and hands-on support utilizing the university's knowledge and network.
Masato Noike, Representative Director and President, Plus Social Investment Inc.
Ritsumeikan Social Impact Fund Investment Limited Partnership
General Partner: Plus Social Investment Inc.
This fund was established with the objective of supporting challenges in solving social issues, as one embodiment of the "Ritsumeikan Vision 2030: More Freedom to Challenge." Flora Inc., through "Wellflow" and "Moonly," comprehensively supports women's specific health issues. Furthermore, the Flora Expert business, which leverages accumulated data, is believed to break through the issue of "data and research shortage" in this field, creating a foundation for a society where everyone can live easily.
We are confident that these businesses will support the well-being of all people and contribute to the realization of a society where everyone can continue to challenge freely, and we look forward to walking together with Flora.
Nagase Future Fund Investment Limited Partnership (NFF)
Nagase Future Fund Investment Limited Partnership (NFF) is a CVC fund operated by Nagase & Co., Ltd. (TSE Prime: 8012). Nagase & Co. was founded in 1832 as a chemical trading company, specializing in the healthcare and beauty sector.